AZITHROMYCIN

Post-LOE

azithromycin

Novartis

ANDAORALTABLET

Approved

Nov 2005

Lifecycle

Post-LOE

Competitive Pressure

60/100

Clinical Trials

Mechanism of Action

[see Microbiology ()] .

Indications (7)

Administration ()]Clinical Studies ()]development of drug-resistant bacteria maintain the effectiveness of azithromycin tablets other antibacterial drugs azithromycin tablets should be used only to treat infections strongly suspected to be caused by susceptible bacteria

Clinical Trials (5)

NCT05772013Phase 4Recruiting

Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations

Started Mar 2024

1,311 enrolled

Chronic Obstructive Pulmonary Disease

NCT06543290Phase 1Recruiting

Azithromycin Before Induction

Started Aug 2023

400 enrolled

Infections

NCT04353661Phase 2Terminated

A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications

Started Nov 2021

12 enrolled

Chronic Obstructive Pulmonary Disease

NCT04349826Phase 4Completed

The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)

Started May 2021

2,150 enrolled

Typhoid Fever

NCT05026801Phase 3Withdrawn

Azithromycin Plus Hydroxychloroquine for COVID-19 Infection

Started Feb 2021

Company

External Resources

Full prescribing information

FDA Drugs@FDA

FDA approval history

RxNorm

Drug nomenclature & identifiers